George M Bright, MD

Vice-president
Versartis, Inc.
Medical Affairs
Papers:
A Phase 1b/2a Study of a New Long-acting Growth Hormone (VRS-317) in Pre-pubertal Children with Growth Hormone Deficiency (GHD)